BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 22318201)

  • 1. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
    Hasselbalch HC
    Blood; 2012 Apr; 119(14):3219-25. PubMed ID: 22318201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
    Hasselbalch HC
    Leuk Res; 2013 Feb; 37(2):214-20. PubMed ID: 23174192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?
    Hasselbalch HC
    Leuk Res; 2014 Oct; 38(10):1230-6. PubMed ID: 25149709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Sankar K; Stein BL; Rampal RK
    Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.
    Hasselbalch HC; Bjørn ME
    Mediators Inflamm; 2015; 2015():102476. PubMed ID: 26604428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
    Hasselbalch HC
    Leuk Res; 2014 Feb; 38(2):263-6. PubMed ID: 23932394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
    Masarova L; Verstovsek S
    Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.
    Skov V; Thomassen M; Kjær L; Ellervik C; Larsen MK; Knudsen TA; Kruse TA; Hasselbalch HC
    PLoS One; 2022; 17(6):e0270669. PubMed ID: 35771847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.
    Mora B; Giorgino T; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Barraco D; Pietra D; Barbui T; Rotunno G; Vannucchi AM; Passamonti F
    Leuk Res; 2018 Jun; 69():100-102. PubMed ID: 29734070
    [No Abstract]   [Full Text] [Related]  

  • 11. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
    Hasselbalch HC; Holmström MO
    Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.
    Andersen M; Sajid Z; Pedersen RK; Gudmand-Hoeyer J; Ellervik C; Skov V; Kjær L; Pallisgaard N; Kruse TA; Thomassen M; Troelsen J; Hasselbalch HC; Ottesen JT
    PLoS One; 2017; 12(8):e0183620. PubMed ID: 28859112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Value of Kozak Gene Polymorphism for Thrombosis in Patients with Philadelphia-Negative MPNs.
    El-Ghonemy MS; El-Ashwah S; Denewer M; Soliman EA; El-Baiomy M; Elkerdawy H; El-Sebaie A
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1195-1201. PubMed ID: 33906312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights.
    Fiorentino V; Tralongo P; Martini M; Betti S; Rossi E; Pierconti F; De Stefano V; Larocca LM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
    Hasselbalch HC
    Expert Rev Hematol; 2014 Apr; 7(2):203-16. PubMed ID: 24524202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
    Anderson JE; Sale G; Appelbaum FR; Chauncey TR; Storb R
    Br J Haematol; 1997 Sep; 98(4):1010-6. PubMed ID: 9326205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.